

Received 30 September 2000; accepted 8 December 2000

[illegible]

* Corresponding author. E-mail: robina@cica.es

The reaction scheme illustrates the synthesis of compound 8 from compound 1. Compound 1 is a substituted furan derivative with a methyl group at position 2, a methyl ester group at position 3, and a 2-hydroxy-2-(hydroxymethyl)ethyl side chain at position 4. The synthesis proceeds via several intermediates:

- Compound 1 is converted to compound 2 (R = H) or compound 3 (R = Ac) via reaction i, ii, where the hydroxyl groups are protected as ethers (OR).
- Compound 1 is converted to compound 4 via reaction iv, v, where the side chain is converted to a 2-azido-2-(hydroxymethyl)ethyl group.
- Compound 4 is converted to compound 5 (R = H) or compound 6 (R = Ac) via reaction i, ii, where the ester group is hydrolyzed to a carboxylic acid group.
- Compound 5 is converted to compound 7 via reaction i, viii, where the amino group is introduced.
- Compound 6 is converted to compound 7 via reaction vii, where the amino group is introduced.
- Compound 7 is converted to compound 8 via reaction ix, x, xi, where the amino group is protected with a Fmoc group.

The structures of the intermediates are shown with their respective substituents and stereochemistry. The stereochemistry of the chiral centers is indicated by wedged and dashed bonds.

0040-4039/01/\$ - see front matter © 2001 Elsevier Science Ltd. All rights reserved.
PII: S0040-4039(00)02266-8


aldose.⁹ We now describe the synthesis of one member of the sub-library Aij (i, $n=3$, configuration: D-arabino) and demonstrate that it can be combined to generate oligomers by applying either solution or solid phase processes.

The polyhydroxy and alkylfuran moieties make these compounds attractive, as complex biochemical processes involve molecular recognition based on polar (e.g. hydrogen bonds) and hydrophobic interactions.¹⁰


The synthesis of the building blocks (Scheme 1) starts from **1**.⁹ Regioselective tosylation, followed by S_N2 displacement with NaN_3 gave the azidoester **4**. Subsequent hydrogenation furnished **5**. Hydrolysis of esters **1** and **4** provided carboxylic acids **2** and **6**, respectively. Reduction of the azide **6** delivered aminoacid **7** which was *N*-protected as the Fmoc derivative **8**. This required protection of the polyol as a polysilyl ether in order to avoid formation of carbonates (a regioselective direct reaction gives complex mixtures and a low yield for **8**). Kooles's procedure¹¹ (TMSCl/py , then FmocCl/py , then H_2O) led to **8** in 95% overall yield.

The strategy of head elongation (Scheme 2) is based on the condensation of acid **2** with the aminoester **5** under Mukaiyama conditions.¹² This gave, after acetylation, the dimeric derivative **9**. The latter was easily hydrolyzed into **10** and coupled again with the aminoester **5** to give the trimer **11**.¹³ When using a mixture of DCM/DMF , the protected per-acetate **3** and **5**, the yield was increased.

For the tail elongation (Scheme 3), the coupling of unprotected **5** and **6** was carried out in DMF with



Scheme 2. Head elongation. *Reagents and conditions:* (a) (i) 2 equiv. Ph_3P , 2 equiv. of PyS-SPy , DMF, 2 equiv. of **5**, 12 h, (ii) Ac_2O , Py, 12 h (54% for two steps); (b) (i) 2 equiv. of Ph_3P , 2 equiv. PyS-SPy , DCM:DMF (3:1), 1 equiv. of **5**, 6 h, (ii) Ac_2O , Py, 12 h (74% for two steps); (c) (i) 1 M NaOH , EtOH, 10 h, 60°C , (ii) IR-120 (H^+), MeOH, (iii) Ac_2O , Py (89% for three steps); (d) b (60% for two steps); (e) NaOMe , MeOH (quant.).




Scheme 3. Tail elongation. *Reagents and conditions:* (a) PyBOP , DIPEA , DMF, 1 equiv. of **6**, 45 min (62%); (b) H_2 , Pd/C , EtOH, 30 min (95%); (c) (i) a, (ii) Ac_2O , Py, 12 h (60% for two steps); (d) NaOMe , MeOH (quant.).

PyBOP (benzotriazolyloxy-trispyrrolidino phosphonium hexafluorophosphate) and DIPEA ¹⁴ (*N,N*-diisopropylethylamine) as activating reagents. After 45 min the dimer **13** was isolated in 70% yield. Reduction of the azide and a subsequent coupling reaction gave the corresponding trimer that was purified in the per-acetylated form **15**¹⁵ in 60% yield.

In order to demonstrate the viability of the use of solid phase techniques for incorporating our scaffold Aij into oligomers, we envisaged the synthesis of the pseudotetrapeptide **21** on a solid support (Scheme 4). We have used the Fmoc strategy and the HMBA-AM resin in which the linker is the 4-hydroxymethyl benzoic acid.¹⁶ The couplings were accomplished without protection of the OH groups of the amino acid **8**. The commercially available Fmoc-glycine was attached to the OH resin using 2,6-dichlorobenzoyl chloride and pyridine.¹⁷ This offers a double advantage: it favours the anchoring to the HO resin by avoiding competitive reactions with the free OH groups of **8**, and facilitates the final cleavage of the oligomer from the resin. Subsequent treatment with piperidine gave the solid-supported amine **18**. The Fmoc-aminoacid **8** was then coupled by treatment with PyBOP and DIPEA in DMF, affording the immobilized dimer **19**. The process was repeated twice to obtain the polymer-bound compound **20** that was removed from the solid support with 1 M NaOH and THF as co-solvent to assist swelling of the resin. The aminoacid **21**¹⁸ presents high water solubility. This method could provide a library of oligomers with high bioavailability.

In conclusion, we have synthesized a new class of compounds that represent new leads for combinatorial chemistry in glycopeptidomimetic design. The ease of preparation, their structural diversity with respect to



Scheme 4. Solid phase synthesis: Fmoc strategy. *Reagents and conditions:* (i) 2,6-dichlorobenzoyl chloride, py, DMF, Fmoc-Gly-OH; (ii) 20% PIP/DMF; (iii) PyBOP, DIPEA, DMF, 1 equiv. of **8**; (iv) 1 M, NaOH, THF; (v) 1 M AcOH (60% overall).

functionality and stereochemistry and their stability may lead to new bioactive compounds.

Acknowledgements

We thank Dr. Corinne Kay (Glaxo Wellcome Cambridge Laboratory) for her valuable advice and help in the performance of the solid phase synthesis, Professor Pierre Vogel (University of Lausanne) for helpful discussions, the Dirección General de Investigación Científica y Técnica of Spain (Grant No PB 97-0730) and Junta de Andalucía (FQM 134) for financial support, and the University of Seville for a fellowship to A.J.M.-V. This work is part of the European COST D13 Program, working group COST D13/0001/98.

References

- Kirshenbaum, K.; Zuckermann, R. N.; Dill, K. A. *Curr. Opin. Struct. Biol.* **1999**, *9*, 530–531.
- Giannis, A.; Kolter, T. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 1244–1267.
- (a) Gante, I. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 1699–1720; (b) Liskamp, R. M. J. *Recl. Trav. Chim. Pays-Bas* **1994**, *113*, 1–19; (c) Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 11871.
- Apella, D. H.; Christianson, L. A.; Klein, D. A.; Powell, D. R.; Huang, X.; Barchi, J. J.; Gellman, S. H. *Nature* **1997**, *387*, 381.
- Nicolaou, K. C.; Flörke, H.; Egan, M. G.; Barth, T.; Estevez, V. A. *Tetrahedron Lett.* **1995**, *36*, 1775.
- Yoshimoto, S.; Ichikawa, M.; Hildreth, J. E. K.; Ichikawa, Y. *Tetrahedron Lett.* **1996**, *37*, 2549.
- (a) Park, W. K. C.; Auer, M.; Jaksche, H.; Wong, C.-H. *J. Am. Chem. Soc.* **1996**, *118*, 10150–10155; (b) Ramamoorthy, P. S.; Gervay, J. *J. Org. Chem.* **1997**, *62*, 7801–7805.
- Smith, M. D.; Fleet, G. W. J. *J. Peptide Sci.* **1999**, *5*, 425 and references cited therein.
- García González, F.; Gómez Sánchez, A. *Adv. Carbohydr. Chem.* **1965**, *20*, 303.
- (a) Silverman, D. N.; Lindskog, S. *Acc. Chem. Res.* **1988**, *21*, 30; Greener, B.; Rose, J. *Chem. Commun.* **1999**, 2362; (b) Lehn, J. M. *Supramolecular Chemistry—Concepts and Perspectives*; VCH: Weinheim, 1995.
- Koole, L. H.; Moody, H. M.; Broeders, N. L. H. L.; Quaedflieg, P. J. L. M.; Kuijpers, W. H. A.; van Genderen, M. H. P.; Coenen, A. J. J. M.; van der Wal, S.; Buck, H. M. *J. Org. Chem.* **1989**, *54*, 1657.
- Mukaiyama, T. In *Challenges in Synthetic Organic Chemistry*; Rowlinson, J. S., Ed.; Clarendon Press: Oxford, 1994.
- Selected data for **11**: δ_C (125.7 MHz, $CDCl_3$) 170.3–169.2 (10C), 163.3, 163.2, 163.1, 159.4, 157.4, 157.3, 146.7, 146.6, 146.5, 116.2, 116.1, 114.3, 110.4, 108.5, 108.4, 70.6, 70.5, 69.9, 69.5, 69.4, 68.6, 65.8–65.7, 61.4, 60, 38.2, 38.1, 20.6–20.4 (10C), 14.1, 13.6, 13.3.
- Coste, J.; Le-Nguyen, D.; Castro, B. *Tetrahedron Lett.* **1990**, *31*, 205.
- Selected data for **15**: δ_C (75.4 MHz, $CDCl_3$) 170.5–169.2 (9C), 163.3, 163.2, 163.1, 159.4, 157.6, 157.4, 146.7, 146.5, 146.3, 116.1, 114.3 (3C), 110.4, 108.5 (3C), 70.5, 70.4, 70.3, 69.4, 69.3, 69.2, 65.6–65.5 (3C), 60.1, 50.1, 38.1, 38.0, 20.7–20.5 (9C), 14.1, 13.6, 13.3.
- Atherton, E.; Sheppard, R. C. In *Solid Phase Peptide Synthesis. A Practical Approach*; Rickwood, D. R.; Jones, B. D., Eds.; IRL Press: Oxford, 1989.
- Sieber, P. *Tetrahedron Lett.* **1987**, *28*, 6147.
- Selected data for **21**: δ_C (125.7 MHz, D_2O) 178.0, 168.0, 167.4, 157.9, 157.8, 152.9 (3C), 116.8 (3C), 108.0, 107.8 (3C), 75.2, 70.8, 70.7, 68.7, 67.8, 67.6, 44.4, 43.2, 42.8 (2C), 14.1, 14.0 (3C).